Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 174

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 174
---
 may be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures.

102

Adaptive Biotechnologies CorporationNotes to Consolidated Financial Statements (Continued) 

3.RevenueWe disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our disaggregated revenue for the periods presented (in thousands): 

        Year Ended December 31,

        2024

        2023

        2022

        MRD revenue

        Service revenue
         
        $
        133,029

        $
        102,739

        $
        81,144

        Regulatory milestone revenue

        12,500

        —

        6,000

        Total MRD revenue

        145,529

        102,739

        87,144

        Immune Medicine revenue

        Service revenue

        19,976

        24,959

        31,777

        Collaboration revenue

        13,452

        42,578

        66,387

        Total Immune Medicine revenue

        33,428

        67,537

        98,164

        Total revenue
         
        $
        178,957

        $
        170,276

        $
        185,308

      During the year ended December 31, 2024, we recognized $1.2 million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2024, we recognized $6.5 million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and cancelled customer contracts. During the year ended December 31, 2023, we recognized $0.6 million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $5.6 million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements. During the year ended December 31, 2022, we recognized $0.7